Effect of Science Research Wellness Ndo1 on Glycaemia in Adults With Pre-diabetes
Launched by WELLIZEN AUSTRALIA · Mar 24, 2025
Trial Information
Current as of April 30, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a supplement called Science Research Wellness Ndo1 to see how it affects blood sugar levels in adults with prediabetes. Prediabetes means that a person's blood sugar is higher than normal but not high enough to be diagnosed as diabetes. Over 12 weeks, participants will take two capsules of the supplement each day and will also visit the clinic twice for blood tests to check their blood sugar levels and other health measures. The goal is to find out if this supplement can help improve these health indicators compared to a placebo, which is a look-alike pill that contains no active ingredients.
To be eligible for the trial, participants must be 18 years or older and have prediabetes, which can be confirmed through specific blood tests. They should also be able to read and write in English and have internet access. During the study, participants need to maintain their usual diet and lifestyle and avoid starting other supplements or participating in other studies. It's important to note that some medical conditions and medications may exclude someone from participating, so interested individuals should review the criteria carefully. Overall, this trial aims to explore a potential new way to help manage blood sugar levels in people with prediabetes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18 years and over.
- • 2. Prediabetes, defined as fasting plasma glucose of 6.1-6.9 mmol/L and/or HbA1c of 5.7-6.4% and/or 2 h plasma glucose of 7.8-11.0 mmol/L after ingestion of 75 g of oral glucose load. Blood tests conducted within 3 months before randomisation will be accepted.
- • 3. Able to read and write English.
- • 4. Has access to internet.
- • 5. Provided informed consent to participate in the study.
- Exclusion Criteria:
- • 1. Has a medical condition known to affect the glycaemia.
- • 2. Regular intake of a health supplement with effects on glycaemia.
- • 3. Currently participating in another trial/study of a supplement or drug.
- • 4. Has any known food or allergy or intolerances to the ingredients of the intervention.
- • 5. Pregnant, trying to conceive or breastfeeding.
- • 6. Has any current substance abuse (including tobacco, alcohol and recreational drugs) or currently in substance withdrawal.
- • 7. Moderate to severe medical conditions (defined as a significant impact on social areas of functioning).
- • 8. Any medical conditions that was not stable over the last 3 months.
- • 9. Taking any prescription medication known to affect glycaemia or had a change in their medication within the last 3 months.
- • 10. Currently taking celiprolol, metformin, or any angiotensin-converting enzyme inhibitor medications.
- • 11. Major medical or surgical event requiring hospitalization within the last 3 months.
- • 12. Any other medical reason that may make participation in this study pose a risk to the participant, including potential herb-drug interactions, at the discretion of the study medical supervisor.
About Wellizen Australia
Wellizen Australia is a leading clinical trial sponsor dedicated to advancing innovative healthcare solutions through rigorous research and development. With a strong commitment to improving patient outcomes, Wellizen collaborates with healthcare professionals and institutions to conduct high-quality clinical trials across various therapeutic areas. The organization prioritizes ethical standards and patient safety, leveraging cutting-edge methodologies and technologies to ensure the integrity of its studies. Through its strategic partnerships and a focus on scientific excellence, Wellizen Australia aims to contribute significantly to the global medical landscape and foster the development of effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guandong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported